湖北英达律师事务所 关于长江医药控股股份有限公司 2023 年年度股东大会的 法律意见书 中国武汉市新华路 186 号福星国际商会大厦 18 楼 电话：86.27.85350032 传真：86.27.85350997 邮政编码：430022 网址:www.yingdalaw.com 二○二四年五月 英达律师事务所 法律意见书 湖北英达律师事务所 关于长江医药控股股份有限公司 2023 年年度股东大会的 法律意见书 致：长江医药控股股份有限公司 湖北英达律师事务所（下称"本所"）接受长江医药控股股份有限公司（下称 "公司"）委托，指派本所律师宋浩、周凌雷现场见证公司于 2024 年 5 月 21 日 召开的 2023 年年度股东大会（以下简称"本次股东大会"），并根据《中华人民 共和国公司法》（下称"《公司法》"）、《中华人民共和国证券法》（下称"《证 券法》"）、中国证券监督管理委员会发布的《上市公司股东大会规则》（下称 "《股东大会规则》"）等相关法律、法规、规范性文件以及《长江医药控股股份 有限公司章程》（下称"《公司章程》"）的有关规定，就本次股东大会的召集和 召开程序、出席会议人员的资格和召集人资格、 ...

证券代码：300391 证券简称：长药控股 编号：2024-033 长江医药控股股份有限公司 2023年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 特别提示： 1、本次股东大会无增加、变更、否决提案的情况； 2、本次股东大会以现场投票表决和网络投票表决的方式召开。 一、会议召开和出席情况 1、召集人：公司董事会 2、召开方式：现场投票与网络投票相结合的方式 3、召开时间： 1 （1）现场会议时间：2024 年 5 月 21 日（星期二）下午 14：30 （2）网络投票时间：2024 年 5 月 21 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2024 年 5 月 21 日上午 9:15-9:25，9:30-11:30， 下午 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为 2024 年 5 月 21 日 9:15-15:00。 4、股权登记日：2024 年 5 月 14 日（星期二） 5、现场会议召开地点：公司会议室（十堰市郧阳经济开发区天马大道特 69 号） 6、会议主持人：公司代董事长韩庆 ...

证券代码：300391 证券简称：长药控股 编号：2024-032 长江医药控股股份有限公司 关于延期回复深圳证券交易所年报问询函的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 长江医药控股股份有限公司（以下简称"公司"）于 2024 年 5 月 6 日收到 深圳证券交易所创业板公司管理部下发的《关于对长江医药控股股份有限公司 的年报问询函》（创业板年报问询函〔2024〕第 59 号，以下简称"《年报问询 函》"），要求公司就《年报问询函》中的相关问题做出书面说明，在 2024 年 5 月 15 日前将有关说明材料报送深圳证券交易所创业板公司管理部并对外披露， 同时抄送湖北证监局上市公司监管处。 公司在收到《年报问询函》后高度重视，立刻组织相关部门及中介机构对 《年报问询函》所涉及的问题进行逐项落实。为保证回复内容的准确、完整， 经向深圳证券交易所申请，公司将延期至 2024 年 5 月 22 日前完成问询函的回 复工作，及时履行相关信息披露义务。 公司信息披露媒体为《中国证券报》、《证券时报》、《上海证券报》、 《证券日报》及巨潮资讯网，公司发布的 ...

长江医药控股股份有限公司 关于重大诉讼的进展公告 证券代码：300391 证券简称：长药控股 公告编号：2024-030 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 一、诉讼事项受理的基本情况 2024年5月7日，长江医药控股股份有限公司（以下简称"公司"、"长药控 股"）收到湖北省江陵县人民法院执行裁定书(2024)鄂1024执异13号。湖北省江 陵县人民法院所在地为江陵县郝穴镇荆江路174号。诉讼各方当事人如下： 申请人：中甄住工建设科技（湖北）有限公司，法定代表人周海峰； 被执行人：湖北安博制药有限公司，法定代表人张兰；罗明； 被申请人：长江医药控股股份有限公司，法定代表人罗明。 二、有关本案的基本情况 （一）案件调解情况 申请人中甄住工建设科技（湖北）有限公司与被申请人湖北安博制药有限公 司、罗明、通号建设集团有限公司湖北分公司工程合同纠纷案于2024年1月8日强 制执行。执行过程中，中甄住工建设科技（湖北）有限公司申请要求追加长江医 药控股股份有限公司为本案的被执行人，湖北省江陵县人民法院于2024年3月7日 立案。2024年4月3 ...

1.报告期末，你公司关联方湖北长江大药房连锁有限公 司（以下简称"长江大药房"）和罗明对你公司非经营性资 金占用本息余额 1.80 亿元，占公司最近一期经审计归母净 资产的 92.08%，上述事项为年审会计师出具带强调事项段的 无保留意见的审计报告的主要原因。 相关公告显示，2024 年 4 月 28 日，你公司、长江大药 房、罗明及十堰市昊炜生物科技发展有限公司（以下简称"昊 炜生物"）签署了《债权债务转让及资金占用清偿协议》，协 议约定，昊炜生物将对公司享有的 1.80 亿元债权转让给罗 明和长江大药房，同时公司将公司对湖北长江星医药股份有 限公司（以下简称"长江星"）享有的 1.80 亿元债权转让 1 深 圳 证 券 交 易 所 关于对长江医药控股股份有限公司的年报 问询函 创业板年报问询函〔2024〕第 59 号 长江医药控股股份有限公司董事会 ： 我部在对你公司 2023 年度报告事后审查中关注到以下 情况： 给罗明和长江大药房，罗明和长江大药房以其受让的债权用 以解决其对上市公司及长江星的占用资金事宜。抵消完成后， 公司将不需要向昊炜生物偿还 1.80 亿元借款，转由罗明和 长江大药房向昊炜生物偿 ...

Financial Performance - The company reported a significant decline in performance for 2023, with a net profit attributable to shareholders of -605.65 million yuan, marking a substantial decrease compared to previous years[9]. - The company's operating revenue for 2023 was CNY 1,197,562,401.16, a decrease of 25.86% compared to CNY 1,615,322,934.59 in 2022[33]. - The net profit attributable to shareholders was a loss of CNY 605,653,315.00, representing a significant decline of 2,502.35% from a loss of CNY 23,273,315.49 in the previous year[33]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 632,325,941.80, down 727.71% from a loss of CNY 76,394,797.07 in 2022[33]. - The company's cash flow from operating activities showed a net outflow of CNY 147,425,871.69, a decrease of 123.12% compared to a net outflow of CNY 66,075,132.38 in the previous year[33]. - The company's operating profit for the reporting period was -669.71 million, a year-on-year decline of 937.70%[61]. - The company reported a significant asset impairment of -737,599,281.84, accounting for 110.95% of total profits, primarily due to goodwill and fixed asset impairments[87]. Financial Challenges - As of the end of the reporting period, the company had a net asset of 195.12 million yuan, with undistributed profits amounting to -961.75 million yuan, indicating ongoing financial challenges[8]. - The company has a funds occupation issue amounting to 179.66 million yuan, which represents 92.08% of the latest audited net assets[3]. - The company does not plan to distribute cash dividends or issue bonus shares for the fiscal year[15]. - The company has indicated uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years[33]. - The company has recognized asset impairment losses totaling 756 million yuan, including goodwill impairment of 439 million yuan and fixed asset impairment of 96 million yuan[9]. Market Conditions - The company is facing intense market competition in the traditional Chinese medicine sector, leading to a significant decline in revenue and gross margin[9]. - The Chinese traditional medicine market is projected to grow significantly due to an aging population, with an estimated 250 million people aged 65 and older by 2030, representing 16.9% of the population[46]. - The government has introduced multiple policies to strengthen the regulation of the traditional Chinese medicine industry, creating both opportunities and challenges for the sector[46]. - The photovoltaic industry is experiencing a high prosperity cycle, but some segments are facing overcapacity, leading to intensified market competition[48]. Strategic Initiatives - The company plans to focus on its major asset restructuring and cash acquisition of 52.7535% equity in Changjiang Star[25]. - The company aims to leverage the growing health and wellness trend among consumers, driven by rising disposable incomes and increased awareness of health maintenance[46]. - The company is actively involved in the production and sales of traditional Chinese medicine, including herbal pieces and medicinal capsules, establishing a comprehensive industry chain[44]. - The company plans to develop new business areas such as small packaging of traditional Chinese medicine, centralized decoction, and smart pharmacies to enhance its competitive edge[101]. - The company aims to strengthen its core business in traditional Chinese medicine (TCM) manufacturing, focusing on expanding the scale of TCM material planting and processing, leveraging local policy support in Hubei province[102]. Operational Efficiency - The company has implemented strict quality control measures from raw material procurement to production, ensuring compliance with GMP standards[55]. - The company has established a complete industrial chain for traditional Chinese medicine (TCM) from planting to processing and sales, enhancing its market influence and competitive advantage[62]. - The company has implemented cost reduction and efficiency improvement measures, achieving significant cost savings through centralized procurement and optimized supply chain management[63]. - The company aims to improve operational efficiency, targeting a reduction in costs by 5% through process optimization[175]. Research and Development - The company is focusing on technological innovation and process iteration in the photovoltaic sector to stimulate new production demands and accelerate equipment upgrades[49]. - The company is developing a traditional Chinese medicine formulation aimed at treating viral pneumonia and influenza, with a clinical efficacy rate of over 95%[82]. - Research and development investments have increased by 30%, focusing on advanced medical technologies[176]. - The company is actively investing in new product development, with a budget allocation of 200 million yuan for R&D in the next year, focusing on innovative therapies[199]. Governance and Compliance - The company has maintained compliance with legal and regulatory requirements, with no significant discrepancies in corporate governance practices[116]. - The company has established an independent financial accounting department and a financial management system, ensuring financial independence from the controlling shareholder[117]. - The company has implemented a performance evaluation and incentive mechanism for directors, supervisors, and senior management, promoting transparency and fairness[114]. - The company has reported a warning letter from the China Securities Regulatory Commission on September 12, 2023, regarding compliance issues[129]. Shareholder Engagement - The company held a total of four temporary shareholder meetings in 2023, with investor participation rates ranging from 15.05% to 16.16%[118]. - The company is in communication with shareholders regarding the repurchase of shares, ensuring compliance with all obligations[170]. - The company has established a commitment to avoid unnecessary related party transactions with its subsidiaries[168]. - The company is actively managing its commitments to ensure compliance with regulatory requirements and protect shareholder interests[169]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25% based on new product launches and market expansion strategies[196]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 500 million yuan allocated for this purpose[180]. - The company aims to improve operational efficiency by implementing new technologies, which is projected to reduce costs by 15% over the next year[195]. - The company has set a target to increase its gross margin to 60% by optimizing its supply chain and production processes[196].

证券代码：300391 证券简称：长药控股 公告编号：2024-026 长江医药控股股份有限公司 关于关联方非经营性资金占用自查及整改情况的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性陈述或 重大遗漏。 二、整改措施 1、持续完善公司治理，定期检查公司与关联方非经营性资金往来情况，杜绝公司 对关联方不规范使用资金的情况发生。 1 2、公司根据《企业内部控制基本规范》及配套指引的有关要求进一步健全内部控 制制度，完善内控管理体系，规范内控运行程序，提高公司风险防范能力，保护公司资 产安全。 3、完善公司内部审计部门的职能，加强内部审计部门对公司内部控制制度执行情况 的监督力度，提高内部审计工作的深度和广度，加大重点领域和关键环节监督检查力度， 及时发现内部控制缺陷，及时整改降低公司经营风险，促进公司规范运作和健康可持续发 展。为防止公司不规范使用资金的情况发生，公司内审部门将密切关注和跟踪公司大额资 金往来的情况，对疑似资金往来事项，及时向公司董事会审计委员会汇报，督促公司严格 履行相关审批程序。 4、组织公司全体董事、监事、高级管理人员认真学习领会《公司法》《证券法》《 ...

长江医药控股股份有限公司 关于举行2023年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 长江医药控股股份有限公司（以下简称"公司"）《2023年年度报告》已于 2024年4月30日经公司第五届董事会第十五次会议审议通过，详细内容请见2024 年4月30日刊登于《证券时报》、《中国证券报》、《证券日报》、《上海证券 报》与巨潮资讯网的年报相关信息。 公司定于2024年5月16日（星期四）下午3:00-5:00，在全景网举行2023年度 网上业绩说明会。本次年度业绩说明会采用网络远程的方式举行，投资者可登陆 "全景·路演天下"（http://rs.p5w.net）参与本次年度业绩说明会。 证券代码：300391 证券简称：长药控股 公告编号：2024-025 欢迎广大投资者积极参与。 （问题征集专题页面二维码） 特此公告。 长江医药控股股份有限公司董事会 2024年4月30日 届时，公司代董事长韩庆凯先生、独立董事邓远军先生、董事副总经理兼董 事会秘书宁潞宏先生、副总经理杨月晓先生、财务总监杨英环女士将出席本次说 明会。 为充分尊重投资者 ...

Financial Performance - The company's revenue for Q1 2024 was ¥59,091,762.31, a decrease of 56.80% compared to ¥136,792,880.94 in the same period last year[5] - The net loss attributable to shareholders was ¥47,505,902.27, representing a 106.92% increase in losses from ¥22,958,141.64 year-on-year[5] - Net loss for Q1 2024 was ¥81,120,269.42, compared to a net loss of ¥30,813,220.72 in Q1 2023, representing a significant increase in losses[21] - Basic and diluted earnings per share for Q1 2024 were both -¥0.1356, compared to -¥0.0655 in the previous year[22] Cash Flow - The net cash flow from operating activities was negative at ¥32,816,721.93, a decline of 234.82% compared to a positive cash flow of ¥24,341,147.26 in the previous year[5] - Cash inflow from operating activities totaled 59,812,629.83, down 76% from 249,772,840.34 in the previous period[24] - Cash outflow from operating activities increased to 92,629,351.76, compared to 225,431,693.08 in the previous period, reflecting higher operational costs[24] - The ending cash and cash equivalents balance decreased to 2,316,745.24 from 6,054,431.45 in the previous period, indicating liquidity challenges[25] - The company received 10,250,000.00 in cash from borrowings, which was not present in the previous period, suggesting new financing efforts[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,431,968,428.54, a slight decrease of 0.40% from ¥3,445,757,061.65 at the end of the previous year[5] - Total liabilities increased to ¥2,495,767,268.42 from ¥2,428,435,632.11, indicating a rise in financial obligations[18] - The company has a total net asset of RMB 195,121,069.28, with an accumulated loss of RMB 961,745,688.98 and a net profit of RMB -605,653,315.00 for the fiscal year 2023[15] Operational Performance - The weighted average return on net assets was -27.72%, a significant drop from -2.91% in the same period last year[5] - The company’s cash flow from operating activities has been negative for two consecutive years, raising concerns about its ability to continue as a going concern[15] - The company reported a significant increase in interest expenses, totaling ¥12,788,662.59, compared to ¥9,478,334.98 in Q1 2023[21] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,974[10] - The largest shareholder, Changxing Shengshi Fenghua, holds 10.11% of the shares, amounting to 35,423,600 shares, with 21,002,800 shares pledged[10] Research and Development - Research and development expenses decreased by 51.33% to ¥978,777.88 from ¥2,011,134.43 year-on-year, attributed to business delays due to funding issues[8] - Research and development expenses for Q1 2024 were ¥978,777.88, a decrease of 51.4% from ¥2,011,134.43 in the same period last year[20] Fund Occupation and Risks - The company reported a significant fund occupation of RMB 179,662,019.54, accounting for 92.08% of the latest audited net assets attributable to shareholders[12] - The company is at risk of receiving additional warnings on stock trading if it fails to resolve the fund occupation issue by May 30, 2024[14] - The company plans to resolve the fund occupation issue through a debt transfer agreement, which has been approved by the board and awaits shareholder approval[14] Inventory and Receivables - Accounts receivable stood at RMB 1,603,853,809.90, slightly decreasing from RMB 1,639,156,949.32[16] - The company has a total of RMB 53,704,389.97 in inventory, which increased from RMB 51,858,189.15[16] - The company’s prepayments increased to RMB 145,416,454.20 from RMB 120,759,307.99[16]

证券代码：300391 证券简称：长药控股 公告编号：2024-011 长江医药控股股份有限公司 关于子公司重大诉讼的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 原告中铁一局集团有限公司诉被告湖北长江大药房连锁有限公司、罗明、湖 北长江伟创中药城有限公司、湖北长江星医药股份有限公司的建设工程施工合同 纠纷案于2023年8月14日进入强制执行申请阶段，湖北长江大药房连锁有限公司、 公司的子公司湖北长江丰医药有限公司和湖北长江星医药股份有限公司为被执 行人，涉案的金额109,727,911.86元。近日，公司收到中铁一局集团有限公司和 湖北长江大药房连锁有限公司、湖北长江伟创中药城有限公司、湖北长江星医药 股份有限公司签署的执行和解协议。该案涉及的1,152万元预计将对公司损益产 生影响。 一、诉讼事项受理的基本情况 2023年8月21日，长江医药控股股份有限公司（以下简称"公司"、"长药 控股"）收到中铁一局集团有限公司强制执行申请书、湖北省荆州市中级人民法 院受理案件通知书(2023)鄂10执1064号。湖北省荆州市中级人民法院所在 ...